Elucidating the Role of Dose in the Biopharmaceutics Classification of Drugs: The Concepts of Critical Dose, Effective In Vivo Solubility, and Dose-Dependent BCS

被引:20
作者
Charkoftaki, Georgia [1 ]
Dokoumetzidis, Aristides [1 ]
Valsami, Georgia [1 ]
Macheras, Panos [1 ]
机构
[1] Univ Athens, Lab Biopharmaceut & Pharmacokinet, Fac Pharm, Athens 11528, Greece
关键词
BCS; critical dose; DDBCS; dose; effective in vivo solubility; ORAL DOSAGE FORMS; BIOWAIVER MONOGRAPHS; CLINICAL PHARMACOKINETICS; TUBERCULOSIS PATIENTS; DICLOFENAC POTASSIUM; RELEASE FORMULATIONS; MOLECULAR ENTITIES; PRACTICAL EXAMPLES; HEALTHY-VOLUNTEERS; THEORETICAL BASIS;
D O I
10.1007/s11095-012-0815-4
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
To develop a dose dependent version of BCS and identify a critical dose after which the amount absorbed is independent from the dose. We utilized a mathematical model of drug absorption in order to produce simulations of the fraction of dose absorbed (F) and the amount absorbed as function of the dose for the various classes of BCS and the marginal cases in between classes. Simulations based on the mathematical model of F versus dose produced patterns of a constant F throughout a wide range of doses for drugs of Classes I, II and III, justifying biowaiver claim. For Classes I and III the pattern of a constant F stops at a critical dose Dose(cr) after which the amount of drug absorbed, is independent from the dose. For doses higher than Dose(cr), Class I drugs become Class II and Class III drugs become Class IV. Dose(cr) was used to define an in vivo effective solubility as S-eff = Dose(cr)/250 ml. Literature data were used to support our simulation results. A new biopharmaceutic classification of drugs is proposed, based on F, separating drugs into three regions, taking into account the dose, and Dose(cr), while the regions for claiming biowaiver are clearly defined.
引用
收藏
页码:3188 / 3198
页数:11
相关论文
共 67 条
[61]   Impact of the intragastric location of extended release tablets on food interactions [J].
Weitschies, W ;
Wedemeyer, RS ;
Kosch, O ;
Fach, K ;
Nagel, S ;
Söderlind, E ;
Trahms, L ;
Abrahamsson, B ;
Mönnikes, H .
JOURNAL OF CONTROLLED RELEASE, 2005, 108 (2-3) :375-385
[62]   PHARMACOKINETICS OF DICLOFENAC SODIUM FOLLOWING INTRAVENOUS AND ORAL-ADMINISTRATION [J].
WILLIS, JV ;
KENDALL, MJ ;
FLINN, RM ;
THORNHILL, DP ;
WELLING, PG .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 16 (06) :405-410
[63]   Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system [J].
Wu, CY ;
Benet, LZ .
PHARMACEUTICAL RESEARCH, 2005, 22 (01) :11-23
[64]   Identification of Suitable Formulations for High Dose Oral Studies in Rats Using In Vitro Solubility Measurements, the Maximum Absorbable Dose Model, and Historical Data Sets [J].
Wuelfing, W. Peter ;
Kwong, Elizabeth ;
Higgins, John .
MOLECULAR PHARMACEUTICS, 2012, 9 (05) :1163-1174
[65]   The "high solubility" definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs [J].
Yazdanian, M ;
Briggs, K ;
Jankovsky, C ;
Hawi, A .
PHARMACEUTICAL RESEARCH, 2004, 21 (02) :293-299
[66]   An integrated model for determining causes of poor oral drug absorption [J].
Yu, LX .
PHARMACEUTICAL RESEARCH, 1999, 16 (12) :1883-1887
[67]   Compartmental transit and dispersion model analysis of small intestinal transit flow in humans [J].
Yu, LX ;
Crison, JR ;
Amidon, GL .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 140 (01) :111-118